Kamada Ltd
NASDAQ:KMDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kamada Ltd
Cash & Cash Equivalents
Kamada Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash & Cash Equivalents
$75.5m
|
CAGR 3-Years
30%
|
CAGR 5-Years
1%
|
CAGR 10-Years
31%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Cash & Cash Equivalents
$1.9m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-13%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash & Cash Equivalents
$110.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash & Cash Equivalents
$7.1m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
N
|
Neurosense Therapeutics Ltd
NASDAQ:NRSN
|
Cash & Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Cash & Cash Equivalents
$4.7m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-1%
|
|
Kamada Ltd
Glance View
Kamada Ltd. engages in the development and production of pharmaceutical products. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
See Also
What is Kamada Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
75.5m
USD
Based on the financial report for Dec 31, 2025, Kamada Ltd's Cash & Cash Equivalents amounts to 75.5m USD.
What is Kamada Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
31%
Over the last year, the Cash & Cash Equivalents growth was -4%. The average annual Cash & Cash Equivalents growth rates for Kamada Ltd have been 30% over the past three years , 1% over the past five years , and 31% over the past ten years .
